Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.

You may also be interested in...



NicOx Takes It In The Gut: FDA Not Accepting Naproxcinod Claims On Blood Pressure Or GI Safety

FDA reviewers recommend that claims about blood pressure and ulcer benefits not be included in product label, on eve of advisory committee meeting.

NicOx Takes It In The Gut: FDA Not Accepting Naproxcinod Claims On Blood Pressure Or GI Safety

FDA reviewers recommend that claims about blood pressure and ulcer benefits not be included in product label, on eve of advisory committee meeting.

NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate

Deal shows - once again - that all is not lost when Big Pharma hands back a product

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel